“The biggest question that arose from this is, ‘Why is there such a lack of large familial genetic disorder epidemiological studies?’ says Laura Bukavina, MD, MPH.
In this video, Laura Bukavina, MD, MPH, and Sarah P. Psutka, MD, MS, discuss the questions raised by the European Urology study, “Epidemiology of Renal Cell Carcinoma: 2022 Update.” Bukavina is a urologic oncology fellow at Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Psutka is an associate professor of urology at University of Washington Medical Center, Seattle.
Targeted neoadjuvant therapy for high-complexity cases of renal masses in a solitary kidney
September 2nd 2023A Cleveland Clinic study found that TKIs in the neoadjuvant setting are associated with greater use of partial nephrectomy when treating patients diagnosed with renal masses in a solitary kidney.
Adjuvant pembrolizumab DFS benefit in ccRCC sustained across disease subgroups
August 31st 2023The disease-free survival and distant metastasis-free survival benefits observed with adjuvant pembrolizumab in the intent-to-treat population of patients with clear cell renal cell carcinoma extended across all subgroups defined by disease risk, tumor stage, and lymph node involvement.
2 Clarke Drive
Cranbury, NJ 08512